Top Regulatory News Stories – Week Ending July 12, 2019

Karyopharm Therapeutics announced that the U.S. FDA has approved oral XPOVIOTM (selinexor), a nuclear export inhibitor, in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). Alexion’s Soliris received FDA approval for an additional indication last week.  The drug is now approved to treat neuromyelitis optica spectrum[…]